Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers provide details of new studies and findings in the area of breast cancer
June 23rd, 2005
New findings from the United Kingdom and United States describe advances in breast cancer. Study 1: According to published research from England, "Fulvestrant (Faslodex) is a new type of estrogen receptor (ER) antagonist that binds, blocks, and degrades the ER, leading to reduced expression of the progesterone receptor (PgR). "Unlike the selective ER modulator tamoxifen, fulvestrant is devoid of any known agonist activity." N. Bundred, University of South Manchester Hospital, explained, "Fulvestrant has a steroidal structure that competitively binds to the ER with an affinity much greater than that of tamoxifen. After binding to...
Source: Women's Health Weekly (2005-06-23)
|
